Clinical Laserthermia Systems AB Class B (DE:LS60)
FRANKFURT:LS60
Want to see DE:LS60 full AI Analyst Report?
LS60 Stock Chart & Stats
€0.59
<€0.01(0.74%)
At close: 4:00 PM EST
€0.59
<€0.01(0.74%)
Day’s Range― - ―
52-Week Range€0.19 - €1.16
Previous CloseN/A
Volume0.00
Average Volume (3M)75.00
Market Cap
€13.34M
Enterprise Value€100.42M
Total Cash (Recent Filing)€21.55M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta3.69
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding31,163,593
10 Day Avg. Volume175
30 Day Avg. Volume75
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.55
Price to Sales (P/S)10.18
P/FCF Ratio-4.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€5.07M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Clean Balance SheetA near-zero debt position materially reduces financing risk and gives management flexibility to pursue clinical rollouts or partnerships without immediate refinancing pressure. This supports longer-term commercialization efforts and lowers fixed financial costs while adoption ramps.
Recurring Procedure-driven Revenue PotentialThe business model includes consumables and procedure components that generate repeat revenue once systems are installed. That creates a path to annuity-like margins tied to procedure volumes, improving long-term revenue visibility and unit economics as installed base grows.
Specialized Laserthermia Platform And Clinical FocusA focused, differentiated medical device offering tied to image-guided thermal ablation can create durable competitive advantages via clinical data, workflow integration and hospital credentialing. Device specialization supports higher switching costs and long-term installed-base value.
Bears Say
Deep, Persistent LossesVery large negative margins indicate the company is far from self-sustaining profitability. Persistent losses erode equity, limit reinvestment capacity, and increase reliance on external capital. Until margins move meaningfully toward break-even, long-term funding and shareholder dilution remain key risks.
Negative Operating And Free Cash FlowMaterial negative OCF and FCF force dependence on new financing or equity raises, which can dilute investors or impose debt burdens. Large cash burn relative to revenue constrains the company's ability to scale sales, support training, and sustain multi-year clinical validation efforts without external funding.
Small, Volatile Revenue With Recent DeclineLow and inconsistent top-line performance undermines commercialization economics and delays achieving scale benefits from consumables and services. A notable YoY decline signals adoption or market penetration challenges that impede margin improvement and predictable installed-base driven revenue growth.
LS60 FAQ
What was Clinical Laserthermia Systems AB Class B’s price range in the past 12 months?
Clinical Laserthermia Systems AB Class B lowest stock price was €0.19 and its highest was €1.16 in the past 12 months.
What is Clinical Laserthermia Systems AB Class B’s market cap?
Clinical Laserthermia Systems AB Class B’s market cap is €13.34M.
When is Clinical Laserthermia Systems AB Class B’s upcoming earnings report date?
Clinical Laserthermia Systems AB Class B’s upcoming earnings report date is May 15, 2026 which is in 25 days.
How were Clinical Laserthermia Systems AB Class B’s earnings last quarter?
Clinical Laserthermia Systems AB Class B released its earnings results on Feb 20, 2026. The company reported -€0.036 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.036.
Is Clinical Laserthermia Systems AB Class B overvalued?
According to Wall Street analysts Clinical Laserthermia Systems AB Class B’s price is currently Overvalued.
Does Clinical Laserthermia Systems AB Class B pay dividends?
Clinical Laserthermia Systems AB Class B does not currently pay dividends.
What is Clinical Laserthermia Systems AB Class B’s EPS estimate?
Clinical Laserthermia Systems AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinical Laserthermia Systems AB Class B have?
Clinical Laserthermia Systems AB Class B has 31,163,593 shares outstanding.
What happened to Clinical Laserthermia Systems AB Class B’s price movement after its last earnings report?
Clinical Laserthermia Systems AB Class B reported an EPS of -€0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -23.125%.
Which hedge fund is a major shareholder of Clinical Laserthermia Systems AB Class B?
Currently, no hedge funds are holding shares in DE:LS60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinical Laserthermia Systems AB Class B
Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
Technical Analysis
SpectraCure AB
―
Luxbright AB
―
Scandinavian Real Heart AB
―
Nosa Plugs AB
―
Arcoma AB
―